Revenue Growth Across Company
Q1 sales of $2.7 billion, up 6% year-over-year; guidance for constant currency sales growth of 5%–7% for 2026.
Surgical Franchise and Equipment Momentum
Surgical revenue $1.5 billion, up 6% YoY; equipment sales $253 million, up 23% driven by Unity platform adoption and early strong order pipeline.
Contact Lens and Vision Care Strength
Vision Care sales $1.2 billion, up 6% YoY; contact lens sales $738 million, up 4% driven by product innovation (Total30, Precision7) and reusable lens adoption (more than half of new wearers started reusables).
Ocular Health Momentum
Ocular health sales $487 million, up 10% YoY; sustained family of artificial tears grew high single-digits and multi-dose preservative-free formulations grew >20% YoY.
Pharmaceutical Launch Traction — Tryptyr
Tryptyr gained ~4 share points within ~8 months of launch, refill rates >70%, commercial coverage expanded to ~55% of commercial lives with Medicare Part D coverage targeted to expand access further.
IOL Innovation and Share Gains
PanOptix Pro drove share gains (nearly 2 share points in the U.S. PC-IOL category); global AT-IOL penetration up ~130 basis points to ~17% (excluding China up ~220 bps); TruPlus launched with toric option day 1; Vivity upgrade on track for early 2027.
Unity Recognition and Product Extensions
Unity VCS named an Edison Award winner; Unity CS (stand-alone cataract system) well received; Unity platform contributing to expanding installed base and equipment growth.
Capital Allocation and Shareholder Returns
Board approved $1.5 billion share repurchase program over 3 years and shareholders approved a $0.28 per share dividend, supporting return of capital while preserving investment capacity.
Operational Improvements and AI Adoption
Deployment of AI across R&D, operations and commercial functions to increase speed to approval, improve yield/quality and enable deeper customer insights; expected to fortify margin and productivity over time.